Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

s, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc.


'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... BRIDGEWATER, N.J. , Oct. 2, 2014 /PRNewswire/ ... in synthetic biology, and Amneal Pharmaceuticals LLC ... volume in the U.S., today announced the formation ... a target active pharmaceutical ingredient (API).  Utilizing Intrexon,s ... collaboration is to develop a consistent, scalable, and ...
(Date:10/1/2014)...  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ... of high pressure-based sample preparation systems to the life ... to present at the 2 nd  Global Life ... The Conference will take place at the Warsaw Stock ... Schumacher , President and CEO of PBI, will present ...
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Slone ... Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, reported ... positions at the director level and above from July ... to stay on top of rapid breakthroughs in diagnostics, ... many diagnostic companies have been forced to fold, consolidate, ...
Breaking Biology Technology:Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2
... Karudapuram, Ph.D. and David Batey Ph.D. , ... , ... real-time quantitative PCR (qPCR) protocol was used on the MJ Research ... Two hydrolysis probes, one labeled with VIC and the other labeled with FAM, ...
... Ph.D.1, Richard Kurtz, Ph.D.2, David Batey, Ph.D.2 , ... Sciences, Stanford University, Stanford, CA , , ... , ... the amoA gene were used to measure the ammonia-oxidizing bacteria (AOB) population in soils maintained ...
... , AquaPure Genomic DNA Isolation Kit , ... DNA (15-ml tube prep), , Method ... 1. Add 1 ml body fluid (e.g., cerebrospinal fluid, plasma, saliva, serum, , ... , tube containing 5 ml cell lysis solution. Pipet up and ...
Cached Biology Technology:Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 2Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 3Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 4Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 5Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 6Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 7Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 2Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 3Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 4Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 5Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 6Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 7Genomic DNA Isolation From 1 ml of Body Fluid 2
(Date:9/30/2014)... aquatic environment on Earth, but when the climate changes ... the limit. The amount of time needed to adjust ... species cope in the future, reveals a new study ... the scientific journal Proceedings of the Royal Society ... increasing levels of greenhouse gases in the atmosphere. The ...
(Date:9/30/2014)... If you want your doctor to know what goes wrong ... a good idea to know what "normal" actually is. That,s ... issue of the FASEB Journal comes ... complete transcriptomea key set of molecules that can help scientists ... particular time. What,s more, they found never-before-detected gene activity and ...
(Date:9/30/2014)... People who suffer from asthma may think there,s not ... besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the scientific ... Immunology (ACAAI), asthma sufferers can learn lessons about managing ... in the Annals article improved her asthma once she ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... used by bodybuilders could be the key to treating ... new research shows. The amino acid L-tyrosine had ... in laboratory tests on mice, significantly improving symptoms of ... New South Wales (UNSW) found. Trials showed that ...
... The EpiGen Consortium, an international alliance of the ... Sciences of the Agency for Science, Technology and ... Southampton, Medical Research Council Lifecourse Epidemiology Unit, ... announce the creation of a research collaboration with ...
... 22, 2011 /PRNewswire-iReach/ -- Researchers have demonstrated ... Curran eat significantly more fruits and vegetables and get ... 12 months ago.  By participating in the WellSteps ... in nutrition, physical activity, and sleep quality. Employees also ...
Cached Biology News:Hope for muscle wasting disease 2EpiGen announces collaboration with Nestlé 2New Study Shows Impact of Employee Wellness Efforts 2
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: